Pathogen genomic surveillance as a scalable framework for precision phage therapy

Mihály Koncz,Tamás Stirling,Hiba Hadj Mehdi,Orsolya Méhi,Bálint Eszenyi,András Asbóth,Gábor Apjok,Ákos Tóth,László Orosz,Bálint Márk Vásárhelyi,Eszter Ari,Lejla Daruka,Tamás Ferenc Polgár,György Schneider,Sif Aldin Zalokh,Mónika Számel,Gergely Fekete,Balázs Bohár,Karolina Nagy Varga,Ádám Visnyovszki,Edit Székely,Monica Sorina Licker,Oana Izmendi,Carmen Costache,Ina Gajic,Bojana Lukovic,Szabolcs Molnár,Uzonka Orsolya Szöcs-Gazdi,Csilla Bozai,Marina Indreas,Katalin Kristóf,Charles Van der Henst,Anke Breine,Csaba Pál,Balázs Papp,Bálint Kintses
DOI: https://doi.org/10.1101/2024.06.15.599013
2024-06-15
Abstract:Phage therapy is gaining increasing interest in the fight against critically resistant nosocomial pathogens. However, the narrow host range of bacteriophages hampers the development of broadly effective phage therapeutics and demands precision approaches. Here we combine large-scale phylogeographical analysis with high-throughput phage typing to guide the development of precision phage cocktails targeting carbapenem-resistant Acinetobacter baumannii, a top-priority pathogen. Our analysis reveals that a few strain types dominate infections in each world region, with their geographical distribution remaining stable within six years. As we demonstrate in Eastern Europe, this spatio-temporal distribution enables preemptive preparation of region-specific phage collections that target most local infections. Finally, we showcase the efficacy of a four-phage cocktail against the most prevalent strain type in both in vitro and in vivo animal infection models. Ultimately, genomic surveillance identifies patients benefiting from the same phages across geographical scales, thus providing a scalable framework for precision phage therapy.
Microbiology
What problem does this paper attempt to address?